950210.KS
Prestige BioPharma Limited
KSC · Healthcare · Biotechnology · SG
KRW 4,155.00
−1.54%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 26.1B | 26.1B | 14.3B | 689.1M | 161.8M |
| Cost of Revenue | 56.9B | 42.4B | 38.3B | 1.2B | 33.9M |
| Gross Profit | (30.8B) | (16.4B) | (24.0B) | (528.8M) | 127.9M |
| Operating Expenses | |||||
| R&D Expense | 65.7B | 42.5B | 19.1B | 23.4B | 40.9B |
| SG&A Expense | (6.4B) | 19.6B | 23.6B | 45.4B | (53.4B) |
| General & Admin Expense | 899.5M | 1.9B | 3.2B | 17.2B | 28.7B |
| Selling & Marketing Expense | 8.0B | 8.0B | 7.7B | 12.7B | 10.9B |
| Other Expenses | 25.2B | — | 520.0M | (23.4B) | 24.9B |
| Total Operating Expenses | 69.5B | 62.2B | 43.3B | 45.4B | 12.4B |
| Cost and Expenses | 120.1B | 119.7B | 81.6B | 63.5B | 12.4B |
| Operating Income (EBIT) | (93.6B) | (93.6B) | (67.3B) | (62.8B) | 1.0B |
| Non-Operating | |||||
| Interest Income | 14.4B | 3.6B | 9.1B | 12.4B | 10.5B |
| Interest Expense | 17.5B | 6.9B | 7.6B | 7.4B | 950.8M |
| Net Interest Income | (3.1B) | (3.3B) | 1.5B | 5.0B | 9.5B |
| Other Non-Op Income/Expense | (29.4B) | (29.4B) | 71.2B | 8.1B | (3.2B) |
| Non-Operating Income (excl Interest) | 1.0K | — | (78.8B) | (15.0B) | 2.2B |
| EBT (Pre-Tax Income) | (123.0B) | (123.0B) | 3.9B | (54.7B) | (2.1B) |
| Income Tax Expense | (150.1M) | (151.6M) | (248.2M) | 408.7M | 763.3M |
| Bottom Line | |||||
| Net Income | (92.7B) | (91.5B) | 22.3B | (32.9B) | 17.6B |
| Earnings from Cont. Ops | (122.9B) | (122.9B) | 4.2B | (55.1B) | (2.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (92.7B) | (91.5B) | 22.3B | (32.9B) | 17.6B |
| Per Share | |||||
| Basic EPS | (₩1,542) | (₩1,522) | ₩371 | (₩548) | ₩292 |
| Diluted EPS | (₩1,542) | (₩1,522) | ₩371 | (₩548) | ₩292 |
| Revenue Per Share | ₩434 | ₩434 | ₩238 | ₩11 | ₩3 |
| Shares | |||||
| Basic Shares Outstanding | 60.1M | 60.1M | 60.1M | 60.1M | 60.1M |
| Diluted Shares Outstanding | 60.1M | 60.1M | 60.1M | 60.1M | 60.1M |
| Profitability Metrics | |||||
| EBITDA | (60.8B) | (60.8B) | 33.3B | (31.1B) | 10.5B |
| D&A | 32.8B | 32.7B | 21.8B | 16.3B | 11.6B |
| EBIT | (93.6B) | (93.6B) | 11.5B | (47.3B) | (1.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026